Pivekimab sunirine
As of the edition of 20 October 2026, Pivekimab sunirine is an antibody drug conjugate: marketed, first approved in 2026 (US); acts on IL3RA; US protection ends in 2038.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Antibody drug conjugate
- Brand name
- Decnupaz
- First approved
- 27 May 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- AbbVie
- Registered trials
- 5, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Skin and connective tissue
US protection
US protection ends in 2038.
US protection ends in 2038, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by AbbVie. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Pivekimab sunirine.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL3RA | Interleukin-3 receptor subunit alpha | P26951 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 2 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator and Lead sponsor of trials | 2018 to now |